ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ

About

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	--
Market Cap (Mil.):	$593.25
Shares Outstanding (Mil.):	42.62
Dividend:	--
Yield (%):	--

Financials

	CCXI.OQ	Industry	Sector
P/E (TTM):	--	46.63	34.30
EPS (TTM):	-1.13	--	--
ROI:	-33.63	1.55	18.43
ROE:	-34.21	2.77	19.30

Latest News about CCXI.OQ

» More CCXI.OQ News

Competitors

	Price	Change
Johnson & Johnson (JNJ.N)	$86.82	-0.39
GlaxoSmithKline plc (GSK.L)	1,749.50p	+7.50
Merck & Co., Inc. (MRK.N)	$47.16	-0.17
Abbott Laboratories (ABT.N)	$37.76	+0.28
AstraZeneca plc (AZN.L)	3,428.00p	+1.50
Pfizer Inc. (PFE.N)	$29.04	-0.07
Teva Pharmaceutical Industries Limited (TEVA.TA)	14,370.00₪	-350.00
Biogen Idec Inc. (BIIB.OQ)	$235.24	+2.62
Novartis AG (NOVN.VX)	CHF71.25	-0.20
Amgen, Inc. (AMGN.OQ)	$105.91	+0.29

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - CHEMOCENTRYX INC (CCXI-O) Provider: Thomson Reuters Stock Report	$25.00 Buy
ValuEngine Detailed Valuation Report for CCXI Provider: ValuEngine, Inc.	$127.00 Buy
ChemoCentryx, Inc. (CCXI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy
ChemoCentryx Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
CHEMOCENTRYX (CCXI) Zacks Company Snapshot Provider: Zacks Investment Research Inc.	$12.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.